At the upcoming 2025 ASH Annual Meeting, Qihan Biotech will present new data highlighting significant progress across its off-the-shelf and in vivo CAR-T cell therapy programs.

The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B.

Qihan Biotech today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director.

Qihan Biotech announced the publication of groundbreaking clinical results in Cell.